Dr Reddy’s recalls 4,000 units of Tacrolimus in US due to faulty packaging

8 Mar 2023 , 12:45 PM

Dr Reddy’s Laboratories informed that the company is recalling over 4,000 bottles of a generic drug in the United States.

The Hyderabad-based pharmaceutical company is recalling 4,320 bottles of Tacrolimus Capsules, which are used to prevent the body from rejecting an organ transplant. The pharma major is recalling bottles due to a packaging defect.

Dr Reddy’s Laboratories Inc, based in New Jersey, is recalling the affected lot due to the ‘presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labelled as Tacrolimus 0.5 mg capsules,’ according to the USFDA’s latest Enforcement Report.

The affected lot was manufactured at the company’s Bachupally-based manufacturing plant and distributed in the United States by its American subsidiary.

On February 8, this year, Dr Reddy’s began a nationwide Class II recall.

At around 12.42 PM, Dr Reddy’s was trading 0.28% lower at Rs4,428 apiece, against the previous close of Rs4,439.20 on NSE. The counter touched an intraday high and low of Rs4,444 and Rs4,401.25 respectively.

For feedback and suggestions, write to us at [e-mail]